Payment overview · 2025
General Payments
$1,572.74
95 reported records · 15 companies
Healthcare provider profile · identity verified
John D Steffens, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · TWIN FALLS, ID · NPI 1871683409
Verified facts
What the public records show
CMS Open Payments records show John D Steffens, MD received $1,572.74 in general payments during 2025 across 95 reported records.
ABBVIE INC. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $514.79 | 32.7% | 29 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $244.41 | 15.5% | 19 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $163.22 | 10.4% | 17 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $102.75 | 6.5% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $98.12 | 6.2% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $79.90 | 5.1% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.26 | 4.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $63.79 | 4.1% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.01 | 3.4% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $48.73 | 3.1% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$34.22 | 2.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.70 | 2.1% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $22.66 | 1.4% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $21.56 | 1.4% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $20.62 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,572.74 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $352.55 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $328.86 | 20 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $163.22 | 17 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $135.26 | 7 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $102.75 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $98.12 | 5 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $71.26 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $63.79 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $55.90 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $53.01 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $48.73 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $48.73 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 467 | 111 |
| Donepezil Hcl | Donepezil Hcl | 298 | 86 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 260 | 69 |
| Zonisamide | Zonisamide | 239 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 217 | 55 |
| Gabapentin | Gabapentin | 200 | 55 |
| Clonazepam | Clonazepam | 184 | 37 |
| Amantadine | Amantadine Hcl | 167 | 51 |
| Topiramate | Topiramate | 167 | 33 |
| Baclofen | Baclofen | 166 | 40 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 162 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 36 |
| Lamotrigine | Lamotrigine | 121 | 25 |
| Memantine Hcl | Memantine Hcl | 100 | 26 |
| Primidone | Primidone | 94 | 22 |
| Oxcarbazepine | Oxcarbazepine | 87 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 19 |
| Diazepam | Diazepam | 83 | 19 |
| Pregabalin | Pregabalin | 82 | 14 |
| Rasagiline Mesylate | Rasagiline Mesylate | 79 | 23 |
| Ropinirole Er | Ropinirole Hcl | 78 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 21 |
| Dalfampridine Er | Dalfampridine | 76 | 17 |
| Methylphenidate Hcl | Methylphenidate Hcl | 75 | 17 |
| Levetiracetam | Levetiracetam | 71 | 16 |
| Selegiline Hcl | Selegiline Hcl | 64 | 17 |
| Methadone Hcl | Methadone Hcl | 54 | suppressed |
| Prednisone | Prednisone | 54 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Trazodone Hcl | Trazodone Hcl | 52 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 11 |
| Amiloride Hcl | Amiloride Hcl | 48 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Rytary | Carbidopa/Levodopa | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Neupro | Rotigotine | 44 | suppressed |
| Lorazepam | Lorazepam | 40 | 13 |
| Acetazolamide | Acetazolamide | 39 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 36 | suppressed |
| Copaxone | Glatiramer Acetate | 35 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 35 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 32 | suppressed |
| Modafinil | Modafinil | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Teriflunomide | Teriflunomide | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Armodafinil | Armodafinil | 27 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 26 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Glatopa | Glatiramer Acetate | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 20 | suppressed |
| Keppra | Levetiracetam | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Lamictal Xr | Lamotrigine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Zonegran | Zonisamide | 13 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,572.74 · 95 records | ABBVIE INC. | BOTOX, BRIUMVI, Briviact, KESIMPTA, NUPLAZID, Ocrevus Zunovo, PONVORY, QULIPTA, QUTENZA, Rystiggo, TYSABRI, UBRELVY, ULTOMIRIS, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYVGART, ZEPOSIA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error